KPX Lifescience.Co.Ltd Total Liabilities
KPX Lifescience.Co.Ltd total liabilities. Based on the latest financial reports, KPX Lifescience.Co.Ltd (114450) has total liabilities worth ₩15.22 Billion KRW (≈ $10.31 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check KPX Lifescience.Co.Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of KPX Lifescience.Co.Ltd (2014–2024)
Total liabilities of KPX Lifescience.Co.Ltd from 2014 to 2024. This chart illustrates how KPX Lifescience.Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 114450 long-term investment intensity to see how much of total assets are deployed in long-term investments.
KPX Lifescience.Co.Ltd Competitors by Total Liabilities
The table below lists competitors of KPX Lifescience.Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Retractable Technologies Inc
NYSE MKT:RVP
|
USA | $68.26 Million |
|
Astral Asia Bhd
KLSE:7054
|
Malaysia | RM106.03 Million |
|
EL. D. Mouzakis S.A
AT:MOYZK
|
Greece | €23.24 Million |
|
Dayou AP Co.Ltd
KQ:290120
|
Korea | ₩212.01 Billion |
|
Phol Dhanya Public Company Limited
BK:PHOL
|
Thailand | ฿265.30 Million |
|
Mountain Alliance AG
XETRA:ECF
|
Germany | €4.19 Million |
|
Cruzados SADP
SN:CRUZADOS
|
Chile | CL$60.90 Billion |
|
Kumbi Corporation
KO:008870
|
Korea | ₩158.32 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down KPX Lifescience.Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see KPX Lifescience.Co.Ltd total assets.
Liquidity & Leverage Metrics
KPX Lifescience.Co.Ltd Total Liabilities Ratios Explained
KPX Lifescience.Co.Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how KPX Lifescience.Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for KPX Lifescience.Co.Ltd (2014–2024)
The table below shows the annual total liabilities of KPX Lifescience.Co.Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩9.22 Billion ≈ $6.25 Million |
+17.14% |
| 2023-12-31 | ₩7.87 Billion ≈ $5.34 Million |
-19.59% |
| 2022-12-31 | ₩9.79 Billion ≈ $6.64 Million |
-37.54% |
| 2021-12-31 | ₩15.68 Billion ≈ $10.63 Million |
+36.63% |
| 2020-12-31 | ₩11.48 Billion ≈ $7.78 Million |
-0.53% |
| 2019-12-31 | ₩11.54 Billion ≈ $7.82 Million |
+12.43% |
| 2018-12-31 | ₩10.26 Billion ≈ $6.95 Million |
-5.62% |
| 2017-12-31 | ₩10.87 Billion ≈ $7.37 Million |
-29.38% |
| 2016-12-31 | ₩15.39 Billion ≈ $10.43 Million |
+50.15% |
| 2015-12-31 | ₩10.25 Billion ≈ $6.95 Million |
-31.21% |
| 2014-12-31 | ₩14.90 Billion ≈ $10.10 Million |
-- |
About KPX Lifescience.Co.Ltd
KPX Lifescience.Co.,Ltd. engages in development, production, and sale of agrochemical raw materials and pharmaceutical intermediates in South Korea and internationally. The company offers raw materials for pharmaceuticals, pesticides, and primary intermediates to the pharmaceutical and agrochemical markets. It also develops EDP-CL, an intermediate for piperacillin-based antibiotics, including N,N… Read more